Alkermes plc.ALKS
What Alkermes plc. does.
The following discussion contains forward-looking statements. Actual results may differ significantly from those expressed or implied in the forward-looking statements. See “Cautionary Note Concerning Forward-Looking Statements” on page 3 of this Annual Report. Factors that might cause future results to differ materially from those expressed or implied in the forward-looking statements include, but are not limited to, those discussed in “Item 1A—Risk Factors” and elsewhere in this Annual Report.
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Ireland, we also have a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.
In October 2025, we and Avadel Pharmaceuticals plc (“Avadel”) entered into a definitive transaction agreement, subsequently amended in November 2025 (the “Transaction Agreement”), pursuant to which we agreed to acquire the entire issued and to be issued ordinary share capital of Avadel for consideration of (i) $21.00 per ordinary share, nominal value $0.01 per share, of Avadel (each, an “Avadel Share”), payable in cash at closing and (ii) a non-transferable contingent value right (the “CVR”) entitling holders of Avadel Shares to a potential additional cash payment of $1.50 per Avadel Share, contingent upon achievement of a certain specified milestone (the “Avadel Acquisition”). On February 12, 2026, we successfully completed the Avadel Acquisition, adding both LUMRYZ to our portfolio of proprietary commercial products and a commercial organization with experience in narcolepsy.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.2B | $1.1B | $1.7B | $1.6B | $1.5B |
| Net income | -$110.9M | -$48.2M | -$158.3M | $355.8M | $367.1M | $241.7M |
| Free cash flow | $40.6M | $73.7M | -$17.2M | $353.3M | $405.6M | $480.3M |
More on ALKS.
- Alkermes plc. summary
- Alkermes plc. financial statements
- Alkermes plc. key metrics
- Alkermes plc. health scores and style box
- Alkermes plc. earnings
- Alkermes plc. dividends
- Alkermes plc. valuation
- Alkermes plc. ownership and insiders
- Alkermes plc. peers
Figures from Alkermes plc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.